Table 1 |
||||
|
Assumptions for annual transition probabilities, and ranibizumab dosing regimen |
||||
| Ranibizumab treatment |
No ranibizumab treatment |
|||
| Base-case scenario |
Sustained-effect scenario |
Non-sustained-effect scenario |
||
|
|
||||
| Annual transition probabilities* |
||||
| Time horizon |
||||
| Years 1 and 2 |
Results of MARINA, 0.5 mg ranibizumab arm. |
As for base-case |
As for base-case |
Results of MARINA, sham arm. |
| Years 3 and 4 |
Year 2 MARINA data, 0.5 mg ranibizumab arm. |
As for base-case |
Year 2 MARINA data, sham arm |
Year 2 MARINA data, sham arm. |
| Years 5 to 10 |
Year 5 to 10 progression rates of the geographic atrophy form of age-related macular
degeneration |
No further transitions (neither increasing nor decreasing visual acuity) |
Year 2 MARINA data, sham arm, progression rates decreasing by 40% each year |
Year 2 MARINA data, sham arm, progression rates decreasing by 40% each year |
| Ranibizumab dosing regimen |
||||
| One dose monthly for the first 2 years, then every 3 months until end of Year 4. No
ranibizumab thereafter. |
Three doses at monthly intervals, then every 3 months until the end of Year 2. No ranibizumab thereafter. |
One dose monthly for the first 2 years. No ranibizumab thereafter. |
- |
|
|
|
||||
|
MARINA: Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration[2] |
||||
|
Hurley et al. Cost Effectiveness and Resource Allocation 2008 6:12 doi:10.1186/1478-7547-6-12 |
||||
